Masha Fridkis-Hareli, PhD

President, ATR, LLC
Dr. Masha Fridkis-Hareli is an immunologist, consultant, and inventor with over twenty years of experience in academia and industry. She is a founder and president of ATR, LLC, a translational research company providing scientific consulting and laboratory services in assay development for immune disorders. Fridkis-Hareli holds a BA from the Technion, an MS from Hebrew University, and a PhD from the Weizmann Institute of Science in Israel. During her postdoctoral training at Harvard University, she designed and developed a group of novel compounds for treatment of autoimmune diseases currently in phase II clinical trials. After serving as principal investigator at the Dana Farber Cancer Institute, Fridkis-Hareli transitioned to industry where she held a variety of positions with increasing responsibilities at a number of biotechnology companies including Resolvyx Pharmaceuticals, Charles River Laboratories, Taligen Therapeutics, and Alexion Pharmaceuticals. Fridkis-Hareli is a co-author of over 100 publications and seventeen issued patents. She is an adjunct professor at the Boston University School of Medicine and a co-chair of the Drug Discovery Working Group at the Massachusetts Biotechnology Council.


  • PhD Weizmann Institute of Science